Cerebrolysin vs PEG-MGF

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from purified pig brain proteins. It is approved in many countries for stroke, traumatic brain injury, and dementia.

Full details →

PEG-MGF

PEG-MGF (PEGylated Mechano Growth Factor) is a variant of IGF-1 that is produced in response to muscle damage. PEGylation extends its half-life from minutes to several hours, making it practical for use.

Full details →

Side-by-Side Comparison

AspectCerebrolysinPEG-MGF
MechanismContains multiple neurotrophic factors that promote neuroplasticity, reduce neuronal apoptosis, and support synaptic function. Has both neurotrophic and neuroprotective properties.Activates muscle satellite cells (stem cells) and promotes their fusion to existing muscle fibers for repair and growth. MGF is produced naturally in response to mechanical stress on muscles.
Typical DosageClinical dosing: 10-30ml IV daily for acute conditions. Research use: 5-10ml IM daily for cognitive enhancement. Treatment courses typically last 10-20 days.Research protocols typically use 200-400mcg injected into targeted muscle groups 2-3 times weekly, usually post-workout.
AdministrationAdministered via intramuscular or intravenous injection. IV administration is typically used in clinical settings. IM can be used for research purposes.Intramuscular injection, ideally into muscles trained that day. Best administered post-workout when satellite cell activation is relevant.
Side EffectsGenerally well-tolerated. May cause dizziness, headache, sweating, or injection site reactions. Rare cases of agitation or confusion.Injection site soreness, potential hypoglycemia, and localized swelling. Generally well-tolerated.
Best For

What They Have in Common

Both Cerebrolysin and PEG-MGF are commonly used for:

Key Differences

Unique to Cerebrolysin:

Unique to PEG-MGF:

Ready to Learn More?